Hearing on “Examining Patient Access to Investigational Drugs,” Subcommittee on Health (October 3, 2017)
The Subcommittee on Health held a hearing on Tuesday, October 3, 2017, at 10:15 a.m. in 2322 Rayburn House Office Building. The hearing is entitled “Examining Patient Access to Investigational Drugs.”
Memorandum from Ranking Member Pallone to the Subcommittee on Health
Opening Statement of Ranking Member Pallone as prepared for delivery
H.R. 1020, Compassionate Freedom of Choice Act of 2017, To allow the manufacture, importation, distribution, and sale of investigational drugs and devices intended for use by terminally ill patients who execute an informed consent document, and for other purposes.
S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, To authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes.
Representative Andy Biggs (R-AZ)
Representative Brian Fitzpatrick (R-PA)
Scott Gottlieb, M.D.
U.S. Food and Drug Administration
Director, Health Care
U.S. Government Accountability Office (GAO)
Director of Healthcare Policy
Lieutenant Commander Matthew Bellina
U.S. Navy (Retired)
Kenneth I. Moch
President and CEO
Cognition Therapeutics, Inc.
Alison Bateman-House, PhD, MPH, MA
Department of Population Health, New York University (NYU) Langone Health
Ellen V. Sigal
Chairperson and Founder
Friends of Cancer Research